Maria E. Marketou

Dr. Maria E. Marketou

Heraklion University Hospital
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
EVemmanouil vardas
emmanouil vardas
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
PVPanos E Vardas
Panos E Vardas
The European Union's Artificial Intelligence Act (AI Act), published in July 2024, is a pioneering horizontal regulatory framework aimed at ensuring the ethical and safe integration of AI technologies across sectors, including healthcare. While it offers the potential to improve patient care and drive innovation, it also presents challenges for healthcare providers, such as identifying high-risk applications, ensuring transparency in algorithms, and mitigating data bias. However, there are several challenges in its implementation. These include unclear guidance for certain technologies, the need to ensure fairness for diverse patient populations, effective monitoring of AI performance after deployment, and clarifying responsibility in cases of errors. Additionally, varying levels of resources among EU countries may lead to inconsistent implementation of the regulations. This article explores the core elements of the AI Act and its relevance to cardiology and identifies key gaps and unanswered questions that need to be addressed to effectively advance AI-driven medical practices.

19 April 2019 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
SMSpyros Maragkoudakis
Spyros Maragkoudakis
IAIoannis Anastasiou
Ioannis Anastasiou
HNHelen Nakou
Helen Nakou
MPMarina Plataki
Marina Plataki
FPFragiskos I. Parthenakis
Fragiskos I. Parthenakis
Salt has been linked very closely to the occurrence and complications of arterial hypertension. A large percentage of patients with essential hypertension are salt‐sensitive; that is, their blood pressure increases with increased salt intake and decreases with its reduction. For this reason, emphasis is placed on reducing salt intake to better regulate blood pressure. In day‐to‐day clinical practice this is viewed as mandatory for hypertensive patients who are judged to be salt‐sensitive. Previous studies have highlighted the negative effect of high‐salt diets on macrovascular function, which also affects blood pressure levels by increasing peripheral resistances. More recent studies provide a better overview of the pathophysiology of microvascular disorders and show that they are largely due to the overconsumption of salt. Microvascular lesions, which have a major impact on the functioning of vital organs, are often not well recognized in clinical practice and are not paid sufficient attention. In general, the damage caused by hypertension to the microvascular network is likely to be overlooked, while reversion of the damage is only rarely considered as a therapeutic target by the treating physician. The purpose of this review is to summarize the impact and the harmful consequences of increased salt consumption in the microvascular network, their significance and pathophysiology, and at the same time to place some emphasis on their treatment and reversion, mainly through diet.

1 December 2015 in Journal Of Hypertension
Verified
Journal Article
Closed access
VKVasiliki K. Katsi
Vasiliki K. Katsi
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
DVDimitrios A. Vrachatis
Dimitrios A. Vrachatis
AMAthanasios J. Manolis
Athanasios J. Manolis
PNPetros Nihoyannopoulos
Petros Nihoyannopoulos
IKIoannis Kallikazaros
Ioannis Kallikazaros
Age-related macular degeneration (AMD) is one of the main causes of vision loss, especially in the elderly. The involvement of essential hypertension in its pathogenesis has been well covered in the literature since it was first recognized. Hemodynamic abnormalities appear to contribute to AMD, with the renin–angiotensin system playing a significant role. Many studies have demonstrated that high blood pressure is associated with lower choroidal blood flow and disturbed vascular homeostasis in these patients. In addition, AMD is characterized by abnormal neovascularization, to which angiotensin II and growth factors make a large contribution. Most epidemiological studies have found essential hypertension to be a risk factor for AMD. However, although all agree that the strongest predisposing factors are age and smoking, overall there is some inconsistency regarding the exact role of hypertension in its pathogenesis. In particular, there are no data in the literature to support the view that antihypertensive medication and the successful management of hypertension have a positive effect on the clinical outcome of AMD. This reinforces the data indicating that the cause of AMD is multifactorial and suggests that, although essential hypertension probably plays a role, in itself it is unlikely to be a major contributor to the future occurrence of AMD.

4 July 2023 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
NBNatalia Simantiraki Buechler
Natalia Simantiraki Buechler
KFKostantinos Fragkiadakis
Kostantinos Fragkiadakis
APAnthoula Plevritaki
Anthoula Plevritaki
SZStelios Zervakis
Stelios Zervakis
GKGeorge Kochiadakis
George Kochiadakis

28 January 2021 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
EAEleni Angelaki
Eleni Angelaki
Maria E. MarketouMaria E. Marketou
Maria E. Marketou
Georgios D. BarmparisGeorgios D. Barmparis
Georgios D. Barmparis
APAlexandros Patrianakos
Alexandros Patrianakos
PVPanos E. Vardas
Panos E. Vardas
GTGiorgos P. Tsironis
Giorgos P. Tsironis
Cardiac remodeling is recognized as an important aspect of cardiovascular disease (CVD) progression. Machine learning (ML) techniques were applied to basic clinical parameters and electrocardiographic features, in order to detect abnormal left ventricular geometry (LVG) even before the onset of left ventricular hypertrophy (LVH), in a population without established CVD. The authors enrolled 528 patients with and without essential hypertension, but no other indications of CVD. All patients underwent a full echocardiographic evaluation and were classified into 3 groups; normal geometry (NG), concentric remodeling without LVH (CR), and LVH. Abnormal LVG was identified as increased relative wall thickness (RWT) and/or left ventricular mass index (LVMi). The authors trained supervised ML models to classify patients with abnormal LVG and calculated SHAP values to perform feature importance and interaction analysis. Hypertension, age, body mass index over the Sokolow‐Lyon voltage, QRS‐T angle, and QTc duration were some of the most important features. Our model was able to distinguish NG from CR+LVH combined, with 87% accuracy on an unseen test set, 75% specificity, 97% sensitivity, and area under the receiver operating curve (AUC/ROC) equal to 0.91. The authors also trained our model to classify NG and CR (NG + CR) against those with LVH, with 89% test set accuracy, 93% specificity, 67% sensitivity, and an AUC/ROC value of 0.89, for a 0.4 decision threshold. Our ML algorithm effectively detects abnormal LVG even at early stages. Innovative solutions are needed to improve risk stratification of patients without established CVD, and ML may enable progress in this direction.

30 August 2024 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
Mark SchuuringMark Schuuring
Mark Schuuring
RTRoderick Willem Treskes
Roderick Willem Treskes
TCTeresa Castiello
Teresa Castiello
MJMagnus Thorsten Jensen
Magnus Thorsten Jensen
RARuben Casado Arroyo
Ruben Casado Arroyo
LHLoreena Hill
Loreena Hill
The 2021 European Society of Cardiology guideline on diagnosis and treatment of acute and chronic heart failure (HF) and the 2023 Focused Update include recommendations on the pharmacotherapy for patients with New York Heart Association (NYHA) class II–IV HF with reduced ejection fraction. However, multinational data from the EVOLUTION HF study found substantial prescribing inertia of guideline-directed medical therapy (GDMT) in clinical practice. The cause was multifactorial and included limitations in organizational resources. Digital solutions like digital consultation, digital remote monitoring, digital interrogation of cardiac implantable electronic devices, clinical decision support systems, and multifaceted interventions are increasingly available worldwide. The objectives of this Clinical Consensus Statement are to provide (i) examples of digital solutions that can aid the optimization of prescription of GDMT, (ii) evidence-based insights on the optimization of prescription of GDMT using digital solutions, (iii) current evidence gaps and implementation barriers that limit the adoption of digital solutions in clinical practice, and (iv) critically discuss strategies to achieve equality of access, with reference to patient subgroups. Embracing digital solutions through the use of digital consults and digital remote monitoring will future-proof, for example alerts to clinicians, informing them of patients on suboptimal GDMT. Researchers should consider employing multifaceted digital solutions to optimize effectiveness and use study designs that fit the unique sociotechnical aspects of digital solutions. Artificial intelligence solutions can handle larger data sets and relieve medical professionals’ workloads, but as the data on the use of artificial intelligence in HF are limited, further investigation is warranted.